Alteration of Coagulation and Fibrinolysis System According to Right Ventricular Dysfunction in Chronic Obstructive Pulmonary Disease

만성폐쇄성폐질환에서 우심실 기능 부전에 따른 혈액응고 및 섬유소용해계 변화

  • Kim, Young (Department of Internal Medicine, Yonsei University College of Medicine) ;
  • Jang, Yoon Soo (Department of Internal Medicine, Yonsei University College of Medicine) ;
  • Kim, Hyung Jung (Department of Internal Medicine, Yonsei University College of Medicine) ;
  • Kim, Se Kyu (Department of Internal Medicine, Yonsei University College of Medicine) ;
  • Chang, Joon (Department of Internal Medicine, Yonsei University College of Medicine) ;
  • Ahn, Chul Min (Department of Internal Medicine, Yonsei University College of Medicine) ;
  • Kim, Sung Kyu (Department of Internal Medicine, Yonsei University College of Medicine) ;
  • Kwak, Jin Young (Department of Internal Medicine, Presbyterian Medical Center) ;
  • Choi, Jin Hwa (Department of Internal Medicine, Presbyterian Medical Center)
  • 김영 (연세대학교 의과대학 내과학교실) ;
  • 장윤수 (연세대학교 의과대학 내과학교실) ;
  • 김형중 (연세대학교 의과대학 내과학교실) ;
  • 김세규 (연세대학교 의과대학 내과학교실) ;
  • 장준 (연세대학교 의과대학 내과학교실) ;
  • 안철민 (연세대학교 의과대학 내과학교실) ;
  • 김성규 (연세대학교 의과대학 내과학교실) ;
  • 곽진영 (예수병원 내과) ;
  • 최진화 (예수병원 내과)
  • Received : 2006.05.11
  • Accepted : 2006.06.12
  • Published : 2006.06.30

Abstract

Background: Pulmonary hypertension in COPD patients is the result of a direct effect of tobacco smoke on the intrapulmonary vessels with the abnormal production of the mediators that control vasoconstriction, vasodilatation, and vascular cell proliferation, which ultimately lead to aberrant vascular remodeling and physiology. COPD patients are prone to the developmint of an acute and chronic thromboembolism with an elevation of the plasma procoagulant and fibrinolytic markers However, the roles of the coagulation and fibrinolysis system on the right ventricular dysfunction in COPD patients are not well defined. We examined the alteration of the coagulation and fibrinolysis system in COPD patients according to the right ventricular function measured using cardiac multidetector computed tomography (MDCT). Methods: The right ventricular ejection fraction (RVEF) was measured using cardiac MDCT in 26 patients who were diagnosed with COPD according to the definition of the GOLD guideline. The plasma level of thrombin antithrombin (TAT) and plasminogen activator inhibitor (PAI)-1 were measured using an enzyme linked immunoassay. Results: The plasma TAT was markedly elevated in COPD patients ($10.5{\pm}19.8{\mu}g/L$) compared with those of the control ($3.4{\pm}2.5{\mu}g/L$) (p<0.01). However, the plasma PAI-1 in COPD patients ($29.6{\pm}20.7ng/mL$) was similar to that in the controls. The plasma TAT showed a significant inverse relationship with the RVEF measured by the cardiac MDCT in COPD patients (r=-0.645, p<0.01). However, the plasma PAI-1 did not show a relationship with the RVEF (r=0.022, p=0.92). Conclusion: These results suggest that the coagulation system in COPD patients is markedly activated, and that the plasma level of TAT might be a marker of a right ventricular dysfunction in COPD patients.

배 경: COPD 환자에서 흡연은 폐혈관에 직접 작용하여 혈관 수축, 확장 및 혈관세포 증식을 조절하는 매개물질을 분비하여 혈관의 부적절한 개형 및 생리 현상을 초래하여 폐성고혈압을 유발한다. COPD 환자에서는 종종 급성 및 만성 폐혈전증이 일어나고 혈장내 응고전구물질 및 섬유소용해계의 표지자들이 증가되어 있다. 그러나 COPD 환자에서 혈액 응고계 및 섬유소용해계가 우심실 기능 장애에 어떤 기여를 하는지는 잘 알려져 있지 않다. 본 연구에서는 진행된 COPD 환자에서 multidetector CT scan (MDCT)을 이용하여 측정한 우심실 기능에 따른 혈액내 응고계 및 섬유소용해 계의 변화를 알아보고자 하였다. 방 법: GOLD 지침에 따라 COPD로 진단한 26명에서 심장 MDCT scan을 이용하여 우심실 박출계수를 구하였다. 혈액내 thrombin antithrombin (TAT) 및 plasminogen activator inhibitor (PAI)-1은 enzyme linked immunoassay 방법으로 측정하였다. 결 과: COPD 환자의 혈중 TAT는 $10.5{\pm}19.8{\mu}g/L$으로 정상인의 혈중 TAT $3.4{\pm}2.5{\mu}g/L$보다 의미 있게 증가되었으나 (p<0.01) COPD 환자의 혈중 PAI-1는 $29.6{\pm}20.7ng/mL$으로 정상인의 혈중 PAI-1 $25.9{\pm}17.9ng/mL$와 비교하여 의미 있는 변화가 없었다. COPD 환자에서 혈중 TAT는 MDCT scan으로 측정한 우심실 박출계수와 의미 있는 역 상관관계를 보였으나 (r=-0.645, p<0.01) 혈중 PAI-1은 우심실 박출계수와 상관관계를 보이지 않았다 (r=0.022, p=0.92). 결 론: COPD 환자에서 혈중내 응고계는 활성화되어 있으며 혈중 TAT는 우심실 기능 장애의 의미있는 표지자로 사료된다.

Keywords

References

  1. Fletcher C, Peto R. The natural history of chronic airflow obstruction. Br Med J 1977;1:1645-8 https://doi.org/10.1136/bmj.1.6077.1645
  2. Kim DS, Kim YS, Jung KS, Chang JH, Lim CM, Lew WJ, et al. Prevalence of chronic obstructive pulmonary disease in Korea: a population-based spirometry survey. Am J Respir Crit Care Med 2005;172:842-7 https://doi.org/10.1164/rccm.200502-259OC
  3. Murray CJ, Lopez AD. Mortality by cause for eight regions of the world: Global Burden Study. Lancet 1997;349:1269-76 https://doi.org/10.1016/S0140-6736(96)07493-4
  4. Murray CJ,Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 1997;349:1498-504 https://doi.org/10.1016/S0140-6736(96)07492-2
  5. Hansel TT, Barnes PJ. An atlas of chronic obstructive pulmonary disease COPD. 1st ed. New York: Parthenon Publishing; 2004. p. 56-7
  6. Wright JL, Levy RD, Churg A. Pulmonary hypertension in chronic obstructive pulmonary disease: current theories of pathogenesis and their implication for treatment. Thorax 2005;60:605-9 https://doi.org/10.1136/thx.2005.042994
  7. Lopes AA, Caramuru LH, Maeda NY. Endothelial dysfunction associated with chronic intravascular coagulation in secondary pulmonary hypertension. Clin Appl Thromb Hemost 2002;8:353-8 https://doi.org/10.1177/107602960200800407
  8. Hoeper MM, Sosada M, Fabel H. Plasma coagulation profiles in patients with severe primary pulmonary hypertension. Eur Respir J 1998;12:1446-9 https://doi.org/10.1183/09031936.98.12061446
  9. Wedzicha JA, Seemungal TA, MacCallum PK. Paul EA, Donaldson GC, Bhowmik A, et al. Acute exacerbations of chronic obstructive pulmonary disease are accompanied by elevations of plasma fibrinogen and IL-6 levels. Thromb Haemost 2000;84:210-5 https://doi.org/10.1055/s-0037-1613998
  10. Ashitani J, Mukae H, Arimura Y, Matsukura S. Elevated plasma procoagulant and fibrinolytic markers in patients with chronic obstructive pulmonary disease. Intern Med 2002;41:181-5 https://doi.org/10.2169/internalmedicine.41.181
  11. Kim TH, Ryu YH, Hur J, Kim SJ, Kim HS, Choi BW, et al. Evaluation of right ventricular volume and mass using retrospective cardiac multidetector computer tomography: comparison with first-pass radionuclide angiography. Eur Radiol 2005;15:1987-93 https://doi.org/10.1007/s00330-005-2716-y
  12. Park KJ, Kim HJ, Hwang SC, Lee SM, Lee YH, Hahn MH, et al. The imbalance between coagulation and fibrinolysis is related to the severity of the illness and the prognosis in sepsis. Korean J Intern Med 1999;14:72-7 https://doi.org/10.3904/kjim.1999.14.2.72
  13. Naeije R. Pulmonary hypertension and right heart failure in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2005;2:20-2
  14. Naeije R, Barbera JA. Pulmonary hypertension associated with COPD. Crit Care 2001;5:286-9 https://doi.org/10.1186/cc1049
  15. Presberg KW, Dincer HE. Pathophysiology of pulmonary hypertension due to lung disease. Curr Opin Pulm Med 2003;9:131-8 https://doi.org/10.1097/00063198-200303000-00007
  16. Eisenberg PR, Lucore C, Kaufman L, Sobel BE, Jaffe AS, Rich S. Fibrinopeptide A level indicate of pulmonary vascular thrombosis with primary pulmonary hypertension. Circulation 1990;82:841-7 https://doi.org/10.1161/01.CIR.82.3.841
  17. Christ G, Graf S, Huber-Beckmann R, Zorn G, Lang I, Kneussi M, et al. Impairment of the plasmin activation system in primary pulmonary hypertension: evidence for gender differences Thromb Haemost 2001;86:557-62 https://doi.org/10.1055/s-0037-1616086
  18. Alessandri C, Basili S, Violi F, Ferroni P, Gazzaniga PP, Cordova C. Hypercoagulability state in patients with chronic obstructive pulmonary disease. Thromb Haemost 1994;72:343-6
  19. Altman R, Scazziota A, Rouvier J, Gurfinkel E, Favaloro R, Perrone S, et al. Coagulation and fibrinolytic parameters in patients with pulmonary hypertension. Clin Cardiol 1996;19:549-54 https://doi.org/10.1002/clc.4960190706
  20. Kruithof EK, Baker MS, Bunn CL. Biological and clinical aspects of plasminogen activator inhibitor type 2. Blood 1995;86:4007-24
  21. Huber K, Rosc D, Resch I, Schuster E, Glogar DH, Kaindl F, et al. Circadian fluctuations of plasminogen activator inhibitor and tissue plasminogen activator levels in plasma of patients with unstable coronary artery disease and acute myocardial infarction. Thromb Haemost 1988;60:372-6